A double blind study was carried out with placebo and dopaminergic agents in 100 patients with male diabetic sexual impotence. In basal conditions, mean serum FSH, LH, PRL, and T levels did not significantly differ from those found in a normal control group. No significant variations with the exception of PRL reduction were observed after use of the dopaminergic agents. Sexual activity was improved in 50% of cases after 3-4 dihidroxifenilalanine and 10% of those of the placebo group. In patients with bromocriptine, 20% improved their sexual function without changes in those receiving placebo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/01485018108987548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of Popular Smoking Cessation Aids in England and Associations With Quit Success.
JAMA Netw Open
January 2025
Department of Behavioural Science and Health, University College London, London, United Kingdom.
Importance: A wide range of medications, noncombustible nicotine products, behavioral support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness outside of clinical trial settings can support informed decision-making.
Objectives: To provide up-to-date estimates of the prevalence of different smoking cessation aids and associations with quit success and to explore moderation by socioeconomic position.
1-Methylxanthine enhances memory and neurotransmitter levels.
PLoS One
January 2025
Radiant Research Services Pvt. Ltd., Bangalore, India.
1-Methylxanthine (1-MX) is the major metabolite of caffeine and paraxanthine and might contribute to their activity. 1-MX is an adenosine receptor antagonist and increases the release and survivability of neurotransmitters; however, no study has addressed the potential physiological effects of 1-MX ingestion. The aim of this study was to compare the effect of 1-MX on memory and related biomarkers in rats compared to control.
View Article and Find Full Text PDFXanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFPotential of soybean-velvet bean combination tempe in improving cognitive function.
Narra J
December 2024
Department of Nutrition, Faculty of Medicine Science, Universitas Brawijaya, Malang, Indonesia.
Velvet bean is a native Indonesian legume containing L-dopa, yet it remains underutilized. The aim of this study was to analyze the effects of different types of tempe (soybean, velvet bean, and their combination) on cognitive function, brain histology, dopamine levels, and serum β-amyloid in rats, as well as to identify the parameters most influencing cognitive function, including brain mass and volume, hippocampal neuron count, and dopamine and β-amyloid levels. An experimental study was conducted using a completely randomized design with one factor: the protein source of diet.
View Article and Find Full Text PDFClinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression.
J Zhejiang Univ Sci B
January 2025
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Objectives: Whether vortioxetine has a utility as an adjuvant drug in the treatment of bipolar depression remains controversial. This study aimed to validate the efficacy and safety of vortioxetine in bipolar depression.
Methods: Patients with bipolar Ⅱ depression were enrolled in this prospective, two-center, randomized, 12-week pilot trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!